Quest Diagnostics (DGX) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues reached $2.65 billion, up 12.1% year-over-year, with organic growth of 2.4–2.5%, driven by acquisitions, enterprise accounts, advanced diagnostics, and expanded health plan access.

• Adjusted diluted EPS for Q1 2025 was $2.21, up 8.3% year-over-year; reported diluted EPS was $1.94, up 12.8%.

• Net income attributable to the company rose 13.2% to $220 million.

• Reaffirmed full-year 2025 revenue and adjusted EPS guidance, citing resilience despite macroeconomic uncertainty.

• Expanded automation, robotics, and AI initiatives, including collaboration with Google Cloud, to improve quality, productivity, and customer experience.

Financial highlights

• Q1 consolidated revenues: $2.65B, up 12.1% year-over-year; organic revenues up 2.4–2.5%.

• Diagnostic Information Services revenue up 12.7% year-over-year to $2.59B.

• Adjusted operating income: $406M (15.3% margin), up from $349M (14.8%) last year.

• Cash from operations: $314M, up from $154M year-over-year.

• Capital expenditures for Q1 2025 were $117M; full-year guidance is $500M.

Outlook and guidance

• 2025 revenue guidance: $10.7B–$10.85B; adjusted EPS: $9.55–$9.80; reported EPS: $8.62–$8.87.

• Organic revenue growth expected at ~3%, with additional growth from 2024 acquisitions.

• Operating margin expected to expand; net interest expense forecast at ~$275M; adjusted tax rate at ~25%.

• Operating cash flow guidance raised by $50M due to a CARES Act payroll tax credit; projected at ~$1.5B.

• Capital expenditures for 2025 expected at ~$500M, focused on lab automation and IT.